Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 42

Sort by

Sort Order Select

Journal Articles

Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin disease: a first-in-human trial

Ulrich Jäger, Shirley D’Sa, Christian Schörgenhofer, Johann Bartko, Ulla Derhaschnig, Christian Sillaber, Petra Jilma-Stohlawetz, Michael Fillitz, Thomas Schenk, Gary Patou, Sandip Panicker, Graham C. Parry, James C. Gilbert, Bernd Jilma

Blood (2019) 133 (9): 893–901.

https://doi.org/10.1182/blood-2018-06-856930

Published: 2019

Includes: Supplemental data

Journal Articles

Long Term Efficacy, Safety and PK/PD Profile of the Anti-C1s Antibody (BIVV009) in Primary Cold Agglutinin Disease Patients

Ulrich Jaeger, MD, Shirley D'Sa, MD FRCP, FRCPath, Christian Schoergenhofer, MD, Johann Bartko, MD, Christian Sillaber, MD, Petra Jilma-Stohlawetz, MD, Michael Fillitz, MD, Thomas Schenk, MD, Gary Patou, MD, Sandip Panicker, PhD, Graham C Parry, PhD, James C Gilbert, MD, Bernd Jilma, MD

Blood (2017) 130 (Supplement 1): 703.

https://doi.org/10.1182/blood.V130.Suppl_1.703.703

Published: 2017

Journal Articles

Chronic Inhibition of Complement C1s By TNT009 Produces Sustained, Complete Remission in Patients with Severe, Transfusion-Dependent Cold Agglutinin Disease (CAD)

Bernd Jilma, MD, James C Gilbert, MD, Sandip Panicker, PhD, Graham C Parry, PhD, Michael Fillitz, MD, Schenk Thomas, Christian Sillaber, MD, Johann Bartko, MD, Ulrich Jaeger, MD

Blood (2016) 128 (22): 2435.

https://doi.org/10.1182/blood.V128.22.2435.2435

Published: 2016

Journal Articles

Serum Tryptase Is a Strong Predictive Biomarker That Improves Prognostication in Ph+ Chronic Myeloid Leukemia.

Wolfgang R. Sperr, M.D., Thomas Pfeiffer, Michael Kundi, MD, Christian Sillaber, MD, Susanne Herndlhofer, Peter Valent, MD

Blood (2012) 120 (21): 2783.

https://doi.org/10.1182/blood.V120.21.2783.2783

Published: 2012

Journal Articles

High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia

Wolfgang Warsch, Karoline Kollmann, Eva Eckelhart, Sabine Fajmann, Sabine Cerny-Reiterer, Andrea Hölbl, Karoline V. Gleixner, Michael Dworzak, Matthias Mayerhofer, Gregor Hoermann, Harald Herrmann, Christian Sillaber, Gerda Egger, Peter Valent, Richard Moriggl, Veronika Sexl

Blood (2011) 117 (12): 3409–3420.

https://doi.org/10.1182/blood-2009-10-248211

Published: 2011

Includes: Supplemental data

Journal Articles

BCR/ABL+ CML Stem Cells (CD34+/CD38-) Express High Levels of CD33 and Are Responsive to a CD33-Targeting Drug: a New Potential Concept for Eradication of CML Stem Cells.

Harald Herrmann, M.D., Sabine Cerny-Reiterer, D.V.M., Karoline V. Gleixner, M.D., Katharina Blatt, M.Sc., Susanne Herndlhofer, Hermine Agis, M.D., Werner Rabitsch, M.D., Berthold Streubel, M.D., Gerlinde Mitterbauer-Hohendanner, M.D., Wolfgang R. Sperr, M.D., Christian Sillaber, M.D., Peter Valent, M.D.

Blood (2010) 116 (21): 3382.

https://doi.org/10.1182/blood.V116.21.3382.3382

Published: 2010

Journal Articles

The Multi-Kinase/ABL Inhibitor R763/AS703569 Induces DNA Endoreduplication and Apoptosis In Imatinib-Resistant CML Cells and Synergizes with Nilotinib, Dasatinib, and the Plk-1 Inhibitor BI 2536, In Producing Growth Inhibition.

Karoline V. Gleixner, Harald Herrmann, Barbara Peter, Katharina Blatt, Karina Schuch, Winfried F Pickl, Christian Sillaber, Peter Valent

Blood (2010) 116 (21): 3394.

https://doi.org/10.1182/blood.V116.21.3394.3394

Published: 2010

Journal Articles

Nilotinib and Dasatinib Produce Synergistic Growth-Inhibitory Effects In Imatinib-Resistant CML Cells, Including Subclones Bearing the Multi-Resistant BCR/ABL Mutant T315I

Karoline V. Gleixner, Harald Herrmann, Irina Sadovnik, Karina Schuch, Winfried F Pickl, Christian Sillaber, Peter Valent

Blood (2010) 116 (21): 2280.

https://doi.org/10.1182/blood.V116.21.2280.2280

Published: 2010

Journal Articles

Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: role of KIT D816V and effects of various targeted drugs

Karl J. Aichberger, Karoline V. Gleixner, Irina Mirkina, Sabine Cerny-Reiterer, Barbara Peter, Veronika Ferenc, Michael Kneidinger, Christian Baumgartner, Matthias Mayerhofer, Alexander Gruze, Winfried F. Pickl, Christian Sillaber, Peter Valent

Blood (2009) 114 (26): 5342–5351.

https://doi.org/10.1182/blood-2008-08-175190

Published: 2009

Journal Articles

Bosutinib Blocks Lyn and Btk Activation and Synergizes with the KIT D816V-Targeting Drug Midostaurin in Inducing Apoptosis in Neoplastic Human Mast Cells.

Karoline Veronika Gleixner, MD, Matthias Mayerhofer, MD, Gregor Hörmann, Karina Schuch, Sabine Cerny-Reiterer, MD, Barbara Peter, M.V.M, Harald Herrmann, MD, Winfried F. Pickl, MD, Christian Sillaber, Peter Valent, MD

Blood (2009) 114 (22): 1717.

https://doi.org/10.1182/blood.V114.22.1717.1717

Published: 2009

Journal Articles

Revealing Six Phases of CML Stem Cell Development to Explain Clinical Phenomena Seen in TKI-Treated Patients.

Christian Sillaber, Harald Herrmann, MD, Sabine Cerny-Reiterer, MD, Hermine Agis, Wolfgang R Sperr, Peter Valent, MD

Blood (2009) 114 (22): 4263.

https://doi.org/10.1182/blood.V114.22.4263.4263

Published: 2009

Journal Articles

Effects of Bosutinib (SKI-606) in CML: Kinase Target Profile, Effects on BCR/ABL Mutants, and Synergism with Dasatinib in T315I+ Cells

Karoline Veronika Gleixner, MD, Lily L Remsing Rix, Christian Baumgartner, Uwe Rix, Alexander Gruze, Renata Anna Meyer, M.D., Winfried F. Pickl, MD, Christian Sillaber, Martin Augustin, Jeff Till, Giulio Superti-Furga, Peter Valent, MD

Blood (2008) 112 (11): 3195.

https://doi.org/10.1182/blood.V112.11.3195.3195

Published: 2008

Journal Articles

Targeting of heat shock protein 32 (Hsp32)/heme oxygenase-1 (HO-1) in leukemic cells in chronic myeloid leukemia: a novel approach to overcome resistance against imatinib

Matthias Mayerhofer, Karoline V. Gleixner, Julia Mayerhofer, Gregor Hoermann, Eva Jaeger, Karl J. Aichberger, Rene G. Ott, Khaled Greish, Hideaki Nakamura, Sophia Derdak, Puchit Samorapoompichit, Winfried F. Pickl, Veronika Sexl, Harald Esterbauer, Ilse Schwarzinger, Christian Sillaber, Hiroshi Maeda, Peter Valent

Blood (2008) 111 (4): 2200–2210.

https://doi.org/10.1182/blood-2006-11-055723

Published: 2008

Journal Articles

The Plk-1 Inhibitor BI 2536 Counteracts Proliferation and Viability of CML Cells and Synergizes with Imatinib and Nilotinib (AMN107) in Producing Growth Inhibition.

Karoline V. Gleixner, MD, Veronika Ferenc, M.D., Alexander Gruze, Michael Kneidinger, M.D., Christian Baumgartner, M.D., Matthias Mayerhofer, M.D., Winfried F. Pickl, M.D., Christian Sillaber, M.D., Peter Valent, M.D.

Blood (2007) 110 (11): 1046.

https://doi.org/10.1182/blood.V110.11.1046.1046

Published: 2007

Journal Articles

Dasatinib Inhibits the Growth of Neoplastic Human Eosinophils (EOL-1) through Targeting of FIP1L1-PDGFRα.

Christian Baumgartner, MD, Karoline V. Gleixner, M.D., Alexander Gruze, Puchit Samorapoompichit, M.D., Harald Esterbauer, M.D, Winfried F. Pickl, M.D, Christian Sillaber, M.D., Peter Valent, M.D.

Blood (2007) 110 (11): 3559.

https://doi.org/10.1182/blood.V110.11.3559.3559

Published: 2007

Journal Articles

Delineation of a KIT-Independent Oncogenic Pathway in Neoplastic Mast Cells That Involves Lyn and Btk, and Can Be Disrupted by the KIT/Lyn/Btk-Targeting Drug Dasatinib

Karoline V. Gleixner, MD, Matthias Mayerhofer, M.D., Uwe Rix, Ph.D., Gregor Hoermann, Alexander Gruze, Maria-Theresa Krauth, M.D., Winfried F. Pickl, M.D., Christian Sillaber, M.D., Giulio Superti-Furga, Ph.D., Peter Valent, M.D.

Blood (2007) 110 (11): 1541.

https://doi.org/10.1182/blood.V110.11.1541.1541

Published: 2007

Journal Articles

The Plk-1 Inhibitor BI 2536 Counteracts the Growth of Neoplastic Mast Cells and Synergizes with the KIT D816V-Targeting Drug Midostaurin (PKC412) in Producing Growth-Inhibition.

Veronika Ferenc, MD, Karoline V. Gleixner, M.D., Alexander Gruze, M.D., Michael Kneidinger, M.D., Christian Baumgartner, M.D., Matthias Mayerhofer, M.D., Winfried F. Pickl, M.D., Christian Sillaber, M.D., Peter Valent, M.D.

Blood (2007) 110 (11): 3554.

https://doi.org/10.1182/blood.V110.11.3554.3554

Published: 2007

Journal Articles

Liposomal Cytarabine (DepoCyte) for Treatment of Myeloid CNS Relapse in CML Occurring during Therapy with Imatinib.

Karl J. Aichberger, MD, MSci, Susanne Herndlhofer, Hermine Agis, MD, Wolfgang R. Sperr, MD, Werner Rabitsch, MD, Harald Esterbauer, MD, PhD, Paul Knoebl, MD, Christian Sillaber, MD, Ulrich Jaeger, MD, Peter Valent, MD

Blood (2007) 110 (11): 4556.

https://doi.org/10.1182/blood.V110.11.4556.4556

Published: 2007

Journal Articles

Identification of heat shock protein 32 (Hsp32) as a novel survival factor and therapeutic target in neoplastic mast cells

Rudin Kondo, Karoline V. Gleixner, Matthias Mayerhofer, Anja Vales, Alexander Gruze, Puchit Samorapoompichit, Khaled Greish, Maria-Theresa Krauth, Karl J. Aichberger, Winfried F. Pickl, Harald Esterbauer, Christian Sillaber, Hiroshi Maeda, Peter Valent

Blood (2007) 110 (2): 661–669.

https://doi.org/10.1182/blood-2006-10-054411

Published: 2007

Includes: Supplemental data

Journal Articles

Synergistic Growth-Inhibitory Effects of Two Tyrosine Kinase Inhibitors, Dasatinib and PKC412, on Neoplastic Mast Cells Expressing the D816V-Mutated Oncogenic Variant of KIT.

Karoline V. Gleixner, MD, Matthias Mayerhofer, MD, Karoline Sonneck, MD, Alexander Gruze, Puchit Samorapoompichit, MD, Karl J. Aichberger, MD, Francis Y. Lee, PhD, Paul W. Manley, PhD, Doriano Fabbro, PhD, Winfried F. Pickl, MD, Christian Sillaber, MD, Peter Valent, MD

Blood (2006) 108 (11): 526.

https://doi.org/10.1182/blood.V108.11.526.526

Published: 2006

NARROW

Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin disease: a first-in-human trial

Long Term Efficacy, Safety and PK/PD Profile of the Anti-C1s Antibody (BIVV009) in Primary Cold Agglutinin Disease Patients

Chronic Inhibition of Complement C1s By TNT009 Produces Sustained, Complete Remission in Patients with Severe, Transfusion-Dependent Cold Agglutinin Disease (CAD)

Serum Tryptase Is a Strong Predictive Biomarker That Improves Prognostication in Ph+ Chronic Myeloid Leukemia.

High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia

BCR/ABL+ CML Stem Cells (CD34+/CD38-) Express High Levels of CD33 and Are Responsive to a CD33-Targeting Drug: a New Potential Concept for Eradication of CML Stem Cells.

The Multi-Kinase/ABL Inhibitor R763/AS703569 Induces DNA Endoreduplication and Apoptosis In Imatinib-Resistant CML Cells and Synergizes with Nilotinib, Dasatinib, and the Plk-1 Inhibitor BI 2536, In Producing Growth Inhibition.

Nilotinib and Dasatinib Produce Synergistic Growth-Inhibitory Effects In Imatinib-Resistant CML Cells, Including Subclones Bearing the Multi-Resistant BCR/ABL Mutant T315I

Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: role of KIT D816V and effects of various targeted drugs

Bosutinib Blocks Lyn and Btk Activation and Synergizes with the KIT D816V-Targeting Drug Midostaurin in Inducing Apoptosis in Neoplastic Human Mast Cells.

Revealing Six Phases of CML Stem Cell Development to Explain Clinical Phenomena Seen in TKI-Treated Patients.

Effects of Bosutinib (SKI-606) in CML: Kinase Target Profile, Effects on BCR/ABL Mutants, and Synergism with Dasatinib in T315I+ Cells

Targeting of heat shock protein 32 (Hsp32)/heme oxygenase-1 (HO-1) in leukemic cells in chronic myeloid leukemia: a novel approach to overcome resistance against imatinib

The Plk-1 Inhibitor BI 2536 Counteracts Proliferation and Viability of CML Cells and Synergizes with Imatinib and Nilotinib (AMN107) in Producing Growth Inhibition.

Dasatinib Inhibits the Growth of Neoplastic Human Eosinophils (EOL-1) through Targeting of FIP1L1-PDGFRα.

Delineation of a KIT-Independent Oncogenic Pathway in Neoplastic Mast Cells That Involves Lyn and Btk, and Can Be Disrupted by the KIT/Lyn/Btk-Targeting Drug Dasatinib

The Plk-1 Inhibitor BI 2536 Counteracts the Growth of Neoplastic Mast Cells and Synergizes with the KIT D816V-Targeting Drug Midostaurin (PKC412) in Producing Growth-Inhibition.

Liposomal Cytarabine (DepoCyte) for Treatment of Myeloid CNS Relapse in CML Occurring during Therapy with Imatinib.

Identification of heat shock protein 32 (Hsp32) as a novel survival factor and therapeutic target in neoplastic mast cells

Synergistic Growth-Inhibitory Effects of Two Tyrosine Kinase Inhibitors, Dasatinib and PKC412, on Neoplastic Mast Cells Expressing the D816V-Mutated Oncogenic Variant of KIT.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only